» Articles » PMID: 19277788

Liver Resection with Portal Vein Thrombectomy for Hepatocellular Carcinoma with Vascular Invasion

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2009 Mar 12
PMID 19277788
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Hepatocellular carcinoma (HCC) tends to invade the intrahepatic vasculature, especially the portal vein. The presence of portal vein tumor thrombus (PVTT) in patients with HCC is one of the most significant factors for a poor prognosis. The presence of macroscopic PVTT in patients with HCC is also a significant factor for poor prognosis, with a median survival of <3 months without treatment. In surgically resected series, in patients with gross PVTT (PVTT in the portal trunk, its first-order branch, or its second-order branch), the 3-year and 5-year survival rates are reportedly 15% to 28% and 0% to 17%, respectively.

Methods: The patient was a 77-year-old woman with well-compensated hepatitis C virus-related cirrhosis (stage A6 according to Child-Pugh classification) who sought care at our department for vague abdominal discomfort. Triphasic spiral computed tomographic scan confirmed HCC 6 cm in diameter in the left lobe of the liver. In addition, portal vein tumor thrombosis of the left branch that extended to the right portal vein was present.

Results: The procedure included left hepatectomy and en-bloc portal vein thrombectomy with clamping of both the common portal vein trunk and the right portal vein. The portal vein was incised at the bifurcation of the right and left portal veins, and the thrombus was extracted from the incision in the portal vein. With this procedure, we were able to examine under direct vision the exact extent of the portal vein thrombus, and we identified whether the tumor thrombus was adherent to the venous wall or was freely floating in the venous lumen. Portal clamping and length of operation were 16 and 330 minutes, respectively. Intraoperative blood loss was 550 mL. The patient was discharged on postoperative day 6, and she was free of disease at 15 months after surgery.

Discussion: Liver resection should be considered a valid therapeutic option for HCC with PVTT.

Citing Articles

METTL5 serves as a diagnostic and prognostic biomarker in hepatocellular carcinoma by influencing the immune microenvironment.

Wang L, Peng J Sci Rep. 2023; 13(1):10755.

PMID: 37400463 PMC: 10318095. DOI: 10.1038/s41598-023-37807-5.


lncRNA PITPNA-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by upregulating PDGFD.

Yao J, Liu X Aging (Albany NY). 2023; 15(10):4071-4083.

PMID: 37253627 PMC: 10258019. DOI: 10.18632/aging.204566.


ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner.

Wang W, Huang Q, Liao Z, Zhang H, Liu Y, Liu F Exp Hematol Oncol. 2023; 12(1):1.

PMID: 36609413 PMC: 9825045. DOI: 10.1186/s40164-022-00370-2.


lncRNA MIR4435‑2HG promotes the progression of liver cancer by upregulating B3GNT5 expression.

Zhu Y, Li B, Xu G, Han C, Xing G Mol Med Rep. 2021; 25(1).

PMID: 34859256 PMC: 8669657. DOI: 10.3892/mmr.2021.12554.


CircETFA upregulates CCL5 by sponging miR-612 and recruiting EIF4A3 to promote hepatocellular carcinoma.

Lu C, Rong D, Hui B, He X, Jiang W, Xu Y Cell Death Discov. 2021; 7(1):321.

PMID: 34716323 PMC: 8556257. DOI: 10.1038/s41420-021-00710-x.